Skip to main content

Table 2 Associations between the clinical and laboratory characteristics of the patients and SMAD in univariate and multivariate logistic regression analysis

From: Development and external validation of nomograms to predict the risk of skeletal metastasis at the time of diagnosis and skeletal metastasis-free survival in nasopharyngeal carcinoma

Characteristic Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Age (≥ 45 vs. < 45 years) 1.142 0.850–1.535 0.379    
Gender (Male vs. Female) 0.623 0.410–0.946 0.027    
Smoking Status (Present vs. Absent) 1.139 0.993–1.807 0.056    
Drinking Status (Present vs. Absent) 1.038 0.655–1.647 0.873    
Family history (Present vs. Absent) 0.907 0.649–1.267 0.566    
Calcium, mmol/L (≥ 2.4 vs. < 2.4) 0.987 0.734–1.327 0.932    
Phosphorus, mmol/L (≥ 1.15 vs. < 1.15) 0.921 0.685–1.239 0.587    
Magnesium, mmol/L (≥ 0.93 vs. < 0.93) 0.857 0.636–1.154 0.308    
CRP, mg/L (≥ 1.91 vs. < 1.91) 2.167 1.583–2.965 < 0.001    
WBCs, ×109 (≥ 6.9 vs. < 6.9) 1.252 0.931–1.684 0.137    
Neutrophils, ×109 (≥ 4.2 vs. < 4.2) 1.681 1.241–2.276 0.001    
HGB, g/L (≥ 145 vs. < 145) 0.660 0.488–0.893 0.007 0.672 0.477–0.948 0.023
Platelets, ×109 (≥ 229 vs. < 229) 1.462 1.083–1.974 0.013    
ALT, U/L (≥ 22.2 vs. < 22.2) 1.138 0.846–1.530 0.392    
AST, U/L (≥ 21 vs. < 21) 1.290 0.958–1.736 0.093    
ALP, U/L (≥ 70 vs. < 70) 2.807 2.024–3.893 < 0.001 2.148 1.509–3.056 < 0.001
LDH, U/L (≥ 172.2 vs. < 172.2) 2.465 1.789–3.396 < 0.001 1.512 1.069–2.139 0.019
ALB, g/L (≥ 44.9 vs. < 44.9) 0.631 0.466–0.854 0.003    
GLB, g/L (≥ 30.5 vs. < 30.5) 1.105 0.822–1.486 0.507    
Cholesterol, mmol/L (≥ 5.12 vs. < 5.12) 0.746 0.554–1.006 0.055    
T lymphocytes, ×109 (≥ 1.8 vs. < 1.8) 0.852 0.632–1.147 0.290    
Monocytes, ×109 (≥ 0.4 vs. < 0.4) 1.528 1.133–2.062 0.006    
Pathology (Differentiated vs. Undifferentiated 1.078 0.492–2.363 0.852    
Cranial nerve injury (Absent vs. Present) 0.899 0.491–1.646 0.899    
EBV-DNA, copies/ml    < 0.001    < 0.001
  < 1000 1.000 1.000   1.000 1.000  
 1000–9999 1.553 0.952–2.534 0.078 1.293 0.784–2.131 0.314
 10,000–99,999 2.278 1.459–3.558 < 0.001 1.588 0.998–2.530 0.051
 100,000–999,999 5.278 3.354–8.307 < 0.001 3.234 1.982–5.279 < 0.001
  ≥ 1,000,000 18.767 10.822–32.544 < 0.001 10.703 5.876–19.498 < 0.001
T category    0.805    
 1 1.000 1.000     
 2 1.331 0.629–2.818 0.455    
 3 1.319 0.653–2.663 0.440    
 4 1.443 0.692–3.007 0.328    
N category    < 0.001    0.002
 0 1.000 1.000   1.000 1.000  
 1 1.708 0.750–3.893 0.202 1.292 0.559–2.984 0.549
 2 4.988 2.276–10.933 < 0.001 2.924 1.304–6.557 0.009
 3 4.962 2.232–11.035 < 0.001 2.299 0.996–5.306 0.051
 4 6.307 2.504–15.887 < 0.001 2.606 0.983–6.905 0.054
  1. Abbreviations: SMAD skeletal metastasis at the time of diagnosis, WBCs white blood cells, HGB hemoglobin, GLB globulin, ALB albumin, ALT alanine transaminase, AST aspartate transaminase, ALP alkaline phosphatase, LDH lactate dehydrogenase, CRP C-reactive protein, GGT gamma glutamyl transpeptidase, EBV-DNA Epstein-Barr virus DNA, Undifferentiated undifferentiated non-keratinizing carcinoma, Differentiated differentiated carcinoma
\